Subscribe To

Price Alert Latest News Economic Calendar News

ADAP / Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the second quarter ended June 30, 2023, before the US markets open on Wednesday, August 9, 2023. Following the announcement, the Company will host a live conference call at 8:00 a.m. Read More

Demo Live Account See Partner Details

Content Topics

Adaptimmune

Report

2023

Financial

Business

Updates

Wednesday

August

Stock

ADAP

Posted: Aug 3 2023, 13:24

Author Name: Newsfile Corp

ADAP News

By Zacks Investment Research
October 27, 2023

Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights

The latest trading day saw Adaptimmune Therapeutics PLC (ADAP) settling at $0.55, representing a -1.79% change from its previous close.

By Newsfile Corp
October 25, 2023

Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 25, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leade

By Newsfile Corp
August 3, 2023

Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in ce

By Zacks Investment Research
July 6, 2023

Buy 5 Top-Ranked Stocks With Rising P/E in July

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include OpGen (OPGN), Adaptimmune Therapeutics (ADAP),

By Zacks Investment Research
June 19, 2023

GSK Announces Extension of FDA Review for Rare Blood Therapy

GSK announces the FDA's extension of the review period of its new drug application for momelotinib to treat myelofibrosis by three months. A decision

By Zacks Investment Research
May 30, 2023

Down -22.38% in 4 Weeks, Here's Why You Should You Buy the Dip in Adaptimmune Therapeutics PLC (ADAP)

The heavy selling pressure might have exhausted for Adaptimmune Therapeutics PLC (ADAP) as it is technically in oversold territory now. In addition to

By Seeking Alpha
May 12, 2023

Adaptimmune Therapeutics plc (ADAP) Q1 2023 Earnings Call Transcript

Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2023 Earnings Conference Call May 12, 2023 8:00 AM ET Company Participants Juli Miller - Head-Investor

By Newsfile Corp
April 28, 2023

Adaptimmune to Report Q1 2023 Financial and Business Updates on Friday, May 12, 2023

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - April 28, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.